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Corticosterone (CORT) can stimulate growth hormone (GH) cell (somatotroph) 
differentiation and GH secretion on embryonic day (e) 12 but not e20 in the chicken. 
GH induction involves both glucocorticoid receptors (GR) and mineralocorticoid 
receptors (MR); however, this finding has been characterized only on e12. To further 
define changes in somatotroph responsiveness to CORT, pituitary cells obtained on 
e12-e20 were cultured with CORT alone and in combination with T3.  GH secretion 
increased over basal with CORT treatment on e12, e14, e16, and e18, but not e20.  
Contributions of GR and MR in CORT responses were evaluated using GR and MR 
antagonists.  Blocking both receptors was required to abolish the CORT response by 
e12 cells.  The same treatment on e20 decreased GH secretion relative to basal.  We 
conclude that positive somatotroph responses to CORT are lost during embryonic 
development and that both GR and MR mediate CORT-induced GH secretion by 
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The anterior pituitary gland is composed of five distinct types of cells, all of 
which produce and secrete a specific hormone.  Somatotrophs, corticotrophs, 
gonadotrophs, thyrotrophs and lactotrophs secrete growth hormone (GH), 
adrenocorticotropic hormone (ACTH), luteinizing and follicle-stimulating hormones, 
thyroid-stimulating hormone (TSH) and prolactin, respectively (Griffen & Ojeda, 
2000).  Corticotrophs are the first pituitary cell to differentiate, followed by 
gonadotrophs, thyrotrophs, somatotrophs and finally lactotrophs.   
Research conducted in our lab focuses on the differentiation of somatotrophs 
in chickens and the extrapituitary signals that regulate this phenomenon.  The 
glucocorticoid, corticosterone (CORT), is the extrapituitary signal that initiates 
somatotroph differentiation in chickens.  Somatotroph differentiation and the 
regulation of GH secretion are also regulated by the thyroid hormones.  The chicken 
is an ideal model to study anterior pituitary development because maternal 
interactions are not a factor as in mammals.  The egg also allows for easy 
manipulation of the embryo for a multitude of experiments.   
In order to study somatotroph differentiation in the anterior pituitary gland of 
the chicken, several methods have been employed extensively.  Each one has 
advantages and disadvantages, but more importantly, each one reveals a slightly 
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different angle to the overall picture of the differentiation of the anterior pituitary 
gland.    
Whole tissue mount in situ hybridization is a method to detect the presence of 
a mRNA at the tissue level.  To detect chicken GH, construction of a riboprobe is 
necessary, and incubation with the specific riboprobe produces distinct staining in the 
tissue if chicken GH is present.  It is a method useful for making conclusions at the 
whole tissue level after manipulating the entire embryo.  It does not provide 
information at the single cell level.    
Reverse hemolytic plaque assays (RHPA) allows for the detection of protein 
secretion from a single cell.  It is a means of correlating the plaque area produced to 
the amount of a specific protein, for instance GH, secreted.  This assay can only 
detect the presence of the protein if it has been secreted; it lends no evidence to the 
amount of protein remaining inside of the cell. 
Immunocytochemistry (ICC) is an assay to detect the intracellular stores of a 
protein, specifically GH in this case.  Cells are attached to glass slides, fixed, and then 
incubated with a GH polyclonal antiserum.  Cells containing GH stain dark, while 
those that do not remain clear.  This type of assay clearly demonstrates the population 
of somatotrophs in a sample.  It is not able to determine the amount of GH present or 
the rate of secretion by somatotrophs.  However, when used in combination with an 
RHPA, both protein secretion and production can be explored.   
The previous assays can only detect if the protein is present at the single cell 
level.  None of the assays give an exact estimate of the concentration of protein 
 3
secreted.  The radioimmunoassay (RIA) is a method that directly estimates the 
amount of a given protein in a sample.  It can be used to quantify a protein in cell 
culture medium, blood plasma and serum, urine, extracellular fluid or cellular 
fractions.  The protein of interest competes with a radioactively labeled tracer for its 
cognate receptor.  The amount of protein in the sample is inversely proportional to the 
amount of radioactivity counted.  RIA, although highly accurate and able to 
quantitatively estimate the amount of protein present, requires radioactivity training 
and is potentially hazardous to the researcher’s health.  Enzyme-linked 
immunosorbent assay (ELISA) works similarly, but instead of using radioactivity, it 
uses the principles of protein binding and enzymatic activity to estimate the amount 
of protein in a sample.  An ELISA can be completed in one day.  The research 
centered on somatotroph differentiation of the embryonic chicken conducted in our 
lab has exclusively used the methods described previously.       
  Chicken somatotrophs differentiate around e14.  Administration of CORT 
can induce the premature appearance of somatotrophs in cultures of embryonic 
chicken pituitary cells as seen with RHPA and ICC (Porter et al., 1995a).  By late 
embryonic development, existing somatotrophs are no longer responsive to CORT 
when administered during the RHPA (Dean et al., 2001).  Because these two 
observations were made using two different approaches, it is difficult to conclude that 
this apparent change in responsiveness has an underlying reason.  CORT binds with 
both the type I glucocorticoid receptor (MR) and the type II glucocorticoid receptor 
(GR) to affect gene transcription.  The apparent change in responsiveness of 
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somatotrophs to CORT may be due to a change in expression or availability of the 
two types of receptors.  
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 Growth Hormone 
 
GH is a 191-amino acid protein with a molecular weight of 22,650 Da that is 
structurally related to human chorionic somatomammotropin, a peptide produced by 
the placenta (Griffen & Ojeda, 2000).  GH has species specificity due to differences 
in molecular structure, and it is stored in secretory granules in somatotrophs.   The 
GH produced by somatotrophs actually accounts for between 4-8% of the gland by 
dry weight.  One of the transcription factors, Pit-1, that regulates the GH gene has 
was isolated in the chicken pituitary (Van As et al., 2000).  It has 84% homology with 
mouse Pit-1 and 97% homology with rat Pit-1.  The transcription factor was 
detectable in embryonic chicken from e5 onwards.     
Growth hormone releasing hormone (GHRH) is a 44-amino acid peptide 
encoded by a single gene that is primarily localized to the arcuate nucleus and the 
median eminence of the hypothalamus (Griffen & Ojeda, 2000).  Its production in the 
hypothalamus stimulates the release of GH from the anterior pituitary.  
Administration of GHRH can stimulate cultured chicken somatotrophs to release their 
stored GH in vitro, as seen with reverse hemolytic plaque assays (RHPA) (Porter et 
al., 1995).  The effects of GHRH are readily seen after 4 hours and become maximal 
at 8 hours.  Secretion of GH from embryonic chicken somatotrophs is also regulated 
by thyrotropin-releasing hormone (TRH), somatostatin, and insulin-like growth factor 
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1 (IGF-1), as well as ghrelin and GH secretogogue (GHS), although GHRH is still the 
most potent (Dean et al., 1997).     
Metabolic signals also control GH secretion (Griffen & Ojeda, 2000).  When 
exogenous insulin is administered to humans to mimic hypoglycemia results in 
immediate GH upregulation, as does the amino acid arginine when taken orally.  
Conversely, non-esterified fatty acids reduce GH secretion, although the mechanism 
is not well understood. 
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 Corticosterone (CORT) 
 
CORT is a steroid hormone secreted by the cortex of the adrenal gland.  It is 
considered a glucocorticoid and aids in regulation of the conversion of amino acids 
into carbohydrates and glycogen by the liver.  It also assists in the stimulation of 
glycogen formation in other tissues.  One of the enzymes responsible for CORT 
conversion from cholesterol is 3β-HSD (Kanda et al., 2000).  The mRNA that codes 
for this protein was expressed in the chicken embryonic adrenal glands beginning on 
e5.  It had continued expression until e12 when the study was terminated.  The 
mRNA for another enzyme, P450scc, was expressed in the adrenal glands beginning 
on e7.  
The SF-1/Ad4BP gene is the major regulator controlling steroidogenic P-450 
genes (Kudo & Sutou, 1999).  It belongs to the steroid receptor superfamily and is 
expressed in the adrenal cortex, gonads and pituitary gonadotroph.  It plays a critical 
role in the development of the steroidogenic tissues and pituitary gonadotrophs.   
CORT is similar in structure, although somewhat less potent, than the other 
glucocorticoids, cortisol and cortisone (Griffen & Ojeda, 2000).  It is produced in 
response to stimulation by the pituitary hormone ACTH.  In chickens and rats, but not 
in humans and mice, CORT is the predominant glucocorticoid secreted by the adrenal 
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gland.  It is a precursor in the synthesis of aldosterone, another adrenal cortical 
steroid. 
CORT, and glucocorticoids in general, first stimulate and then inhibit GH 
secretion in a dual manner (Griffen & Ojeda, 2000).  CORT is involved in many 
processes and is essential for life.  The process of gluconeogenesis, where protein in 
muscle is converted into glucose for energy, requires the presence of CORT.  CORT 
then decreases the utilization of glucose by cells.  It is necessary for protein and lipid 
metabolism, and it is involved in maintaining normal vascular integrity as well as 
suppressing inflammation.  In the central nervous system, CORT modulates 
perception and emotion.  
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The Thyroid Hormones: T3 and T4
 
The two principal thyroid hormones are thyroxine (3,5,3’,5’-tetraiodo-L-
thyronine; T4) and triiodothyronine (3,5,3’-triiodo-L-thyronine; T3).  The amino acids 
diiodotyrosine and monoidodotyrosine serve as the precursors for the synthesis of 
these hormones.  The more active form, T3, is formed by removing an iodine group 
from thyroxine, catalyzed by 5’-deiodinase.  Plasma T4 can be detected as early as e9 
in the chicken with levels around 2 ng/mL (Scanes et al., 1987).  Plasma T4 levels rise 
steadily throughout chicken embryonic development with a sharp increase (>20 
ng/mL) prior to hatch.  Plasma T3 levels decrease from >2 ng/mL to <1 ng/mL from 
e9 to e11 and then remain low (~1 ng/mL) and relatively constant until e19 when they 
rise dramatically to >5 ng/mL.  While the primary regulator of thyroid gland function 
is pituitary TSH, the hypothalamus also controls thyroid function to a lesser extent 
through release of thyrotropin releasing hormone (TRH).    
Thyrotrophs appear earlier in chicken embryonic development than 
somatotrophs, on e9, and become evenly distributed by e20 (Sasaki et al., 2003).   
Thyroid hormones are thought to enter target cells by passive diffusion, in a manner 
similar to steroid hormones (Griffen & Ojeda, 2000).  However, there is new 
evidence that a carrier system is used and that the receptors are anchored to the 
nucleus through nonhistone nuclear proteins to facilitate gene transcription.  The 
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thyroid hormones function to increase basal metabolism.  Studies in mammals 
demonstrating the combined effects of glucocorticoids and the thyroid hormones have 
shown that these two agents act synergistically (Samuels et al, 1979; Vale et al, 1983; 
Williams et al, 1991).   
 11
Development of the Chicken Anterior Pituitary Gland  
  
Differentiation of Somatotrophs 
 
In chickens, GH mRNA in the cephalic lobe increases from e16 and reaches 
maximum on e20 (Kansaku et al., 1994).  Similar results were seen in the caudal 
lobe, with more GH mRNA localized to the caudal lobe.  After embryonic 
development, GH levels do not vary from pre-laying, laying, 1-week incubation, 3-
week incubation and brooding.  Again, during these life stages, caudal lobe GH 
mRNA was significantly higher than that in the cephalic lobe, although both lobes 
showed no life-stage effect.   
Glucocorticoids from the adrenal gland stimulate the differentiation of 
somatotrophs in the anterior pituitary gland.  Our group has previously shown that 
somatotrophs become a significant population of chicken anterior pituitary cells 
between embryonic day 14 and embryonic day 16 (e14-e16) (Porter et al., 1995a), 
although a few appear as early as e12.  Somatotrophs in culture do not differentiate 
autonomously.  Serum taken from e16 embryos can induce somatotrophs to 
differentiate in vitro.  However, serum taken from e12 embryos cannot induce 
somatotroph differentiation in vitro.  Further, cell division was not necessary for 
induction of somatotroph differentiation (Porter et al., 1995b).   The blood-borne 
signal was determined to be CORT (Morpurgo et al., 1997).  The most effective dose 
of CORT to induce somatotroph differentiation was found to be 2.5 nM.   
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CORT not only induces the appearance of somatotrophs in cell culture, but 
also in living embryos.  In developing embryos, CORT increased significantly 
between e14 and e15 from 11.3 ng/mL to 20.4 ng/mL as measured by RIA, and 
CORT remained at this concentration until e20 when a significant decrease was 
observed (Kalliecharan & Hall, 1974).  Other adrenal steroids, such as cortisol, 
peaked at e15 in the chicken with 22.3 ng/mL, while cortisone peaked at e17 with 
25.7 ng/mL.  Nonadrenal steroids, such as progesterone, exhibited a steady increase 
from e9 to e20 with a peak at e20 with 31.2 ng/mL, a different profile than 
glucocorticoids.   
An alternative study found that serum CORT levels in the embryonic chicken 
was 3.6 ng/mL on e10 and three times as much (9.0 ng/mL) on e20, determined by 
RIA (Scott et al., 1981).  CORT steadily rose during the last half of incubation.  In 
this study, embryos were staged according to their middle toe length, an important 
indicator of developmental age.  Serum levels of CORT on e10 through e16 were 
statistically different from the previous day.  However, serum levels on e16 through 
e20 were not statistically different from the previous day.   
Exogenous treatment of CORT has different effects on the developing chicken 
embryo (Mashaly et al., 1991).  The dose of CORT injected into the egg was 
determined by weighing of the dry egg before and after injection.  All CORT 
treatments (0.1%, 0.05%, 0.01%) decreased embryo body weight, and embryos 
treated with 0.1% CORT (the highest dose) died by e21.  The mortality rate was 
highest between e19 and e21 for all treatment groups.  The mortality rate did not 
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differ among treatment groups from 4 to 10 days, except for e6, which was higher.  
The control group and 0.01% CORT treatments had lower mortality than the other 
treatment groups.  There was an observable increase in serum CORT levels on e19.  
Specifically, a sharp peak in serum CORT levels occurred at e19 in the 0.01% and 
0.05% treatment groups, and a sharp peak occurred at e17 in the 0.1% treatment 
group.  The 0.1% CORT treatment group had significantly lower overall serum 
CORT levels.  The dose of CORT was determined by weight, which may have been 
too high of a dose to accurately mimic physiologically concentrations.  Plus, CORT 
was given on e0, an age where steroids have proven to be lethal.  This is evidence that 
low doses of CORT may work in a positive feedback manner increasing GH levels at 
appropriate times during development, while higher doses of CORT may work in a 
negative feedback manner decreasing GH levels later in development.  
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The Effects of CORT and GHRH on Somatotroph Differentiation 
  
CORT is known to induce chicken somatotroph differentiation in vitro, and 
GHRH induces the cultured GH cells to release their stored GH (Dean et al., 1997).  
GHRH significantly increases the amount of GH-secreting cells at 10 nM and 100 nM 
on e16 and e18 after an 18 h treatment.  E20 cells are responsive to GHRH at doses 
from 0.01 nM to 100 nM.  This may be due to the already high levels of GH stored in 
the cells.  Sensitivity to GHRH increases in an age-dependent manner between e16 
and e20.   
The combination of CORT and GHRH significantly increased the amount of 
GH secreted by e12 anterior pituitary chick embryonic cells into the cell culture 
medium after two and six days, while neither agent alone had any measurable effect 
(Dean & Porter, 1999).  The same treatments as measured by RHPA showed that 
CORT was able to increase the number of GH-secreting cells alone, and the addition 
of GHRH had no effect after two days, but significantly increased the number of GH-
secreting cells after six days in culture.  As stated previously and reconfirmed with 
these results, CORT induces somatotroph differentiation and increases the number of 
somatotrophs in culture, while GHRH induces the cells to release their stored GH into 
the surrounding environment.   
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Later in development, somatotrophs do not respond as quickly to CORT, but 
respond similarly to GHRH as seen on e12 cells.  Cells obtained from e17 pituitaries 
were able to respond to GHRH alone, however CORT had no effect after two days in 
culture as measured by the amount of GH secreted into the cell culture medium (Dean 
& Porter, 1999).  After six days in culture, GHRH alone had no effect on the amount 
of GH-secreting cells, but the administration of CORT alone and in combination with 
GHRH significantly increased the amount of GH-secreting cells.   
The effects of CORT on somatotrophs are not only seen in chickens, but also 
in mammals.  Glucocorticoids induced somatotroph differentiation in fetal rats in 
vitro using explants of fetal pituitary primordia obtained on day 14 of gestation 
(Hemming, 1988).    In cultured rat pituitary cells obtained from 13.5 day old fetal rat 
pups and maintained in culture for 8 days, cortisol stimulated the differentiation of 
GH-cells (Sato & Watanabe, 1998).  Similar effects were seen in 16.5 day old fetal 
cells that were maintained in culture for 5 days.   
 The effects of CORT in chickens are also seen at the whole embryo level by 
treating embryos in ovo on e11, a few days before normal somatotroph differentiation 
(Bossis & Porter, 2000).  The somatotroph population as measured by RHPA 
increased significantly by e13 with a treatment dose of 0.2 µg and 2 µg.  The same 
increase in the number of GH secreting cells was seen when treating embryos on e12 
and examining on e14.  But the observed increase in the number of somatotrophs did 
not persist later in development (e16) through post-hatch day (d) 1.  The same doses 
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administered on e8 and e9 and then examined two days later did not result in an 
increase in the number of somatotrophs.  Treatment of 2 µg and 20 µg on e0 resulted 
in full mortality between e4 and e6.  Treatment of 20 µg on e8, e9 and e10 also 
resulted in some mortality, with a higher incidence of mortality occurring when the 
embryos were injected at a younger age.  Incidentally, treating with lower amounts of 
CORT on these same ages had no effect.  Clearly, there is a predetermined timeline of 
when somatotrophs are responsive to CORT, between e11 and e12.  Administration 
of CORT too early in development results in embryonic death and when given later in 
development, the cells are already partially differentiated and not responsive to 
CORT.  
 The effects of CORT and GHRH on somatotroph differentiation involves 
induction of growth hormone gene expression (Porter et al., 2001a).  Somatotroph 
abundance was increased after as little as 16 h with CORT treatment.  After 48 h, 
CORT was able to almost double the percentage of somatotrophs over the 16 h 
treatment group.  When CORT was removed from embryonic serum with an 
antibody, the induction of somatotrophs decreased.  However, the amount of 
somatotrophs was still higher than if the cells had never been exposed to CORT at all.  
This finding is strengthened with the fact that administration of CORT directly 
increases GH mRNA.  Addition of GHRH did not augment the effect of CORT, but it 
was able to induce GH secretion after 2 and 4 h, although not after 8 or 20 h.  TRH 
had a similar effect as GHRH.  
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Although CORT increases GH mRNA, the induction of GH gene expression 
is delayed and requires protein synthesis (Bossis & Porter, 2003).  But the identity of 
the protein(s) required is not known.  Induction of GH gene expression may involve 
one or several signal transduction cascades.  Through the use of signaling cascade 
enzyme inhibitors, it was found that the PKA and PKC signal transduction cascades 
do not mediate the effects of CORT.  On the other hand, a RAS GTPase is involved 
in this process.  Further, this is independent of MAPK activation (Porter & Bossis, 
2003).    
 It has been established that administration of CORT induces chicken 
somatotroph differentiation on e12, resulting in an increase in GH secretion.  
Premature somatotroph differentiation induced by CORT has been well established 
using RHPA to measure both the numbers of cells containing GH and the relative 
amount of GH secreted into the extracellular space.  ICC and RIA have also been 
employed to elucidate the ontogeny of GH secreting cells in culture.  However, when 
1 nM of CORT was administered to e16, e18, and e20 cells in culture, there was no 
effect on the number of GH-secreting cells after 24 h of incubation (Porter & Dean, 
2001).  Using RHPA, it was difficult to determine the optimum amount of time in 
culture so that noticeable effects in GH secretion could be detected.  After e16, 
constitutive GH secretion produces plaques in the RHPA around almost all 
somatotrophs.  By examining GH secretion after 6, 12, and 18 h in culture, the 
differences in the effects of CORT, if any, could not be determined. No significant 
differences were seen after 6 h in culture in e16, e18, and e20 cells.  After 12 h of 
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incubation, no effect was seen with e16 and e18 cells, however, this treatment was 
slightly stimulatory on e20.  Alternatively, after 18 h of incubation, CORT did 
produce an increase of GH with e16 and e18 cultured somatotrophs, but not e20.  
During the final quarter of embryonic development, basal levels of GH were almost 
maximal.  This could be why CORT was unable to elicit a large response after e16.  
This apparent change in responsiveness to CORT over the last half of embryonic 
development warrants a more thorough investigation because the studies using e12 
and e16, e18, and e20 were conducted under slightly different culture systems, times, 
CORT concentrations and assay methods.   
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The Effects of CORT and the Thyroid Hormones on Somatotroph 
Differentiation in vivo and in vitro 
 
The thyroid hormones, T3 and T4, are also able to regulate somatotroph 
differentiation.  Pax8-/- mice are born athyroid to euthyroid dams and have a deletion 
in the paired box transcription factor Pax8 (Friedrichsen et al., 2004). These mice are 
an ideal model to study congenital hypothyroidism.  In 21 day old Pax8-/- mice, 
expression of GH was significantly reduced compared to wild-type littermates.  The 
expression of GH mRNA and protein in the anterior pituitary was greatly reduced.  
When the mice were treated with 20 ng of T4 per gram of body weight, GH 
expression increased to wild-type levels.   
In chickens, T3 significantly reduced GH secretion by e16 cells after 16 hrs in 
culture.  Again, there was no effect of T3 on e18 or e20 (Porter & Dean, 2001).  The 
combination of CORT and T3 was inhibitory on e16-e20, with secretion of GH by e16 
somatotrophs being most affected.  Subsequently, it was found that T3 has a biphasic, 
dose-dependent, effect on the abundance of GH-secreting cells in cultures of e11 
pituitary cells (Liu et al, 2003).  At low doses (10-11and 10-10 M), GH cells increase 
beyond the observed CORT response.  However, at higher doses (10-9and 10-8 M), the 
CORT response was suppressed.  This was seen after culturing for both 3 days and 6 
days.  It was also revealed that T4 must be converted to T3 for modulation of 
somatotroph abundance by T4.   
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In rats, when the dam is given T3 and T4, plasma GH concentrations and 
pituitary somatotroph numbers of the fetus are increased (De Escobar et al., 1993).  
This effect is only seen late-term at 18 to 21 days of gestation. T3 has also been 
shown to increase GH levels in fetal day 19 rats (Rodriguez-Garcia et al., 1995).   
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The Effects of Synthetic Glucocorticoids (Dexamethasone) on Somatotroph 
Differentiation  
  
Dexamethasone (DEX) is similar to CORT in structure and action.  Pregnant 
rats were given DEX in their drinking water for 40 hrs before sacrifice (Nogami et 
al., 1993).  This treatment increased GH cells in the anterior pituitary gland of the 
fetus on fetal day 18.  The observed effect was decreased earlier in development, as 
seen in the diminished effect observed on day 17 and the nonexistent effect on day 
16.  Administration of DEX to the pregnant mother in her drinking water elicited an 
induction of GH-cell differentiation in the fetal rat pups.  Normally, somatotroph 
differentiation is not observed until e18, and under these conditions, somatotrophs 
differentiated on e17.  However, injection of DEX failed to produce these same 
results.   
Administration of DEX and T4 augmented the previously observed increase in 
somatotroph differentiation (Nogami et al., 1995).  The addition of methimazole, an 
agent that prevents the conversion of T4 to T3, abolished these observed effects. 
DEX increases GH mRNA-containing cells obtained from e18 rat pituitary 
cells; however, the increase observed never exceeded that of intact e19 rat pituitary 
cells (Nogami et al., 1997).  The same treatment on e16 did not show this, implying 
that somatotrophs are responsive to glucocorticoids at distinct time points during 
development.  The DEX-induced increase of GH-containing cells was not observed 
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after 5 or 10 h and was only observed after a full 24 h.  As in chickens, the addition of 
a protein synthesis inhibitor completely abolished the DEX-induced increase in GH 
positive cells.  
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Type I (Mineralocorticoid) and Type II (Glucocorticoid) Receptors 
in Relation to CORT regulation of Somatotroph Differentiation 
 
Mineralocorticoid and Glucocorticoid Receptors 
 
 Both GR and MR belong to the steroid/thyroid/retinoid/orphan (STRO) 
receptor superfamily.  This superfamily of receptors has over 150 members, including 
the progesterone receptors (PR) and androgen receptors (AR).  GR and MR bind to 
hormone response elements (HRE) and regulate transcription (Funder, 1997).  Both 
of these receptors consist of three functional domains: the carboxy-terminal ligand 
binding domain (LBD), the central DNA-binding domain (DBD), and the amino 
terminus transactivation domain.  The amino terminus varies in size and displays no 
sequence conservation between the two receptors (Rupprecht et al, 1993).  The GR 
and MR differ by only three AA in their DNA binding domains (Berger et al., 1996).  
Valine 571 infers specificity between the MR and GR, preferentially binding 
glucocorticoids over mineralocorticoids (Lind et al., 1999).     
 The human glucocorticoid receptor (GR) has two forms: a ligand-binding 
GRα of 777 amino acids and a 742-amino acid β isoform (Funder, 1997).  The β 
isoform differs only in the last fifteen amino acids and does not bind active 
glucocorticoids.  GRβ is expressed at varying levels in a range of tissues and may act 
as a ligand-independent negative regulator of glucocorticoid action.   Some reports 
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show that GRα exhibits high affinity for dexamethasone, modest affinity for cortisol 
and corticosterone and low affinity for aldosterone (Funder, 1997).  The human 
mineralocorticoid receptor (MR) consists of 984 amino acids and has 57% amino acid 
identity with GRα  in the ligand binding domain and 94% in the DNA binding 
domain.   
GR and MR are located throughout the body, in both epithelial and non-
epithelial tissues, such as the kidney, colon, salivary glands and heart (Griffen & 
Ojeda, 2000; Funder, 1997).  Substantial amounts of both GR and MR are localized 
in the anterior pituitary.  MR also has significant levels in the hippocampus and the 
septum, while GR has high levels in the cerebellum.  Only small amounts of GR are 
found in the renal medulla (Reul et al, 1990). 
 The main difference reported between these two receptors, besides the 
physiological and clinical differences of their cognate ligands, is the ability of GR to 
self-synergize (Funder, 1997).  Super-additive effects are possible with this receptor 
when multiple HREs bind in an N-terminal dependent fashion.  
 In the absence of a ligand, GR and MR are complexed with heat shock 
proteins (hsp) in the cytoplasm, rendering both unable to translocate to the nucleus to 
initiate transcription (Schulman et al., 1994; Funder, 1997).  Upon ligand binding, the 
GR or MR dissociates from hsp, whereupon it can then travel to the nucleus to initiate 
transcription of specific glucocorticoid response genes. 
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 Through the use of knock-out mice, the functions of GR and MR have been 
examined (Berger et al., 1996).  In GR knock-out mice, an 80% lethality rate among 
the homozygous mutants was observed at four weeks of age.  The surviving 
homozygotes showed no abnormalities, were fertile and reached a normal age. 
However, they had increased serum levels of ACTH, the pituitary hormone that 
regulates glucocorticoid release.  Immediately after birth, the mutants had acute 
respiratory distress due to severe lung atelectasis in part due to the impaired 
expression of epithelial sodium channels and synthesis of the surfactant protein.  As 
stated previously, glucocorticoids function in gluconeogenesis, and several enzymes 
important in this process were reduced in livers from mutant mice.  In addition, the 
adrenal glands were enlarged and disorganized, and increased levels of steroidogenic 
enzymes (P450scc and 3β-HSD) were detected.   
 Alternatively, MR knockout mice die around day 10 after birth (Berger et al., 
1996).  Weight loss precedes death and there is an increase in the hematocrit, believed 
to be due to impaired sodium retention in the kidney.  Plasma renin concentration is 
increased by 400%, aldosterone is increased 40-fold and angiotensin II is increased 
55-fold.  Clearly, the ligands that bind to these receptors, as well as the factors that 
regulate both the ligands and receptors, are essential for life.   
 Another study using cultured rat embryos and an antagonist specific for MR, 
ZK91587, demonstrated how essential mineralocorticoid signaling is for normal 
development (Mirshahi et al., 2002).  Adverse effects on total length, somite number 
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and embryo curvature were observed.  Plus, communication between the vitelline and 
umbilical blood vessels in the allantoid was severely affected.  Administration of 
aldosterone reversed these effects.  Other developmental effects were observed in the 
limbs, optic stalk and brain formation.  Similar, but less dramatic results were seen 
with RU26752 (anti-MR) and RU38486 (anti-GR). 
 The concentration of glucocorticoids can affect receptor levels in specific 
tissues (Erdeljan et al., 2001). GR was highest in the hippocampal pyramidal neurons, 
with appreciable amounts in glial cells.  MR was detected in pyramidal neurons, with 
no expression in glial cells.  DEX (10 and 100 nM) exposure decreased GR mRNA 
levels in pyramidal neuorns.  However, DEX had no significant effect on MR mRNA 
levels.  CORT also downregulated GR mRNA expression, but had no effect on MR 
mRNA levels.  The neurotransmitter, serotonin increased GR mRNA levels; MR 
mRNA levels were not affected.  Glial cells were not affected by any treatment. 
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Agonists and Antagonists to GR and MR 
  
Because GR and MR are highly homologous to each other, it is difficult to 
find specific ligands that will only activate one, but not the other receptor (Raynaurd 
et al, 1980).  The steroid hydroxyl groups confer specificity between receptors; DEX 
is most specific to GR, while the adrenal steroid, aldosterone (ALDO), is most 
specific to MR (Hellal-Levy et al., 1999).  However, at varying concentrations, 
steroids have the ability to cross-bind with alternative receptors.  Therefore, the 
agonists and antagonists and their respective concentrations have been carefully 
studied so as to define the specificity of the receptors and the ligands.   
Binding data (Kd) and Skatchard analyses given below for the various 
compounds were determined from a standard binding assay.  In brief, the competition 
of each synthetic or natural compound for either GR or MR was measured in high-
speed supernatants or “cytosols”, which were prepared from receptor-rich target 
organs (Raynaurd et al, 1980).  The receptor is singled out with radiolabeled ligands, 
either the natural hormone or a potent synthetic agonist.  Relative binding affinities 
(RBAs) were measured under two or three different sets of incubation conditions so 
as to give an accurate indication of the kinetics of the test-compound/receptor 
interaction. 
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The MR agonist, aldosterone, is the principal mineralocorticoid.  It acts 
primarily in the adrenal gland and functions to regulate sodium balance in urine 
(Griffen & Ojeda, 2000).  Aldosterone binds both MR (Ki=0.08 nM) and GR (Ki=63 




Table 1:  Relative affinities of agonists and antagonists to the glucocorticoid and
mineralocorticoid receptors.  The name of the ligand is given in the left column
with its dissociation constant (Ki) for both GR and MR.  The reference is given in
parenthesis.  Multiple Ki’s are reported for conflicting information. 
 Affinity for GR (Ki) Affinity for MR (Ki) 
Aldosterone 63 nM (Rupprecht, 1993) 
11.89 nM (Reul, 1990) 
0.09 nM (Rupprecht, 1993) 
0.20 nM (Reul, 1990) 
Corticosterone 4.90 nM (Reul, 1990) 
5.14 nM (Kd) (Svec, 1984) 
______ 
0.05 nM (Reul, 1990) 
Cortisol 15 nM (Rupprecht, 1993) 
5.00 nM (Reul, 1990) 
0.13 nM (Rupprecht, 1993) 
0.19 nM (Reul, 1990)  
Dexamethasone 1.1 nM (Rupprecht, 1993) 
7.75 nM (Reul, 1990) 
8.5 nM (Kd) (Svec, 1984) 
1.1 nM (Rupprecht, 1993) 
0.42 nM (Reul, 1990) 
RU 28362 _______ 
0.39 nM (Reul, 1990) 
>1000 nM (Rupprecht, 1993) 
________ 
RU 38486 2.2 nM (Rupprecht, 1993) 
27.90 nM (Reul, 1990) 
________ 
>1000 nM (Reul, 1990) 
Spironolactone 79 nM (Rupprecht, 1993) 
260 nM (Reul, 1990) 
5.7 nM (Rupprecht, 1993) 
3.25 (Reul, 1990) 
Triamcinolone 
Acetonide 
3.4 nM (Kd) (Svec, 1984) _________ 




  The MR antagonist, spironolactone, is a synthetic steroid with a structure 
similar to aldosterone, and it competes with aldosterone for binding sites on MR 
(Rupprecht et al, 1993).  Spironolactone thus inhibits sodium and water reabsorption, 
while sparing potassium and magnesium.  It has high affinity for MR, but relatively 
low affinity for GR.  Its Ki for GR is 79 nM, while its KI for MR is 5.7 nM, a ten-fold 
difference between the two.   
The GR agonist, triamcinolone acetonide (TA), is a synthetic glucocorticoid.  
Biopotency to bioaffinity have been compared when examining the effectiveness of 
glucocorticoids (Svec, 1984).  Binding data and Skatchard analysis can highlight 
binding affinities of certain ligands towards their receptors, but it does not necessarily 
explain biopotency discrepancies in regards to ligand concentration.  It was found that 
TA at a concentration of 1 nM almost completely inhibited ACTH secretion in the 
mouse pituitary tumor cell line, the AtT-20, but at that same concentration, binding 
analysis revealed that only 10-20% of the cell’s receptors were occupied.  Binding 
data ranks triamcinolone acetonide (Kd=3.4 nM) as the glucocorticoid with the 
highest affinity for GR, before dexamethasone (Kd=8.5 nM) and corticosterone 
(Kd=51 nM).    
The GR antagonist, ZK98299, is a synthetic glucocorticoid known to displace 
progesterone from its binding sites on GR.  It has strong antagonistic activities, 
resulting in antigestational effects on the organism.  In human myometrium cells, 
ZK98299 binds to PR, although with lower affinity than progesterone (D’souza et al., 
1994).  The binding lasts about 6 h, and the binding sites were saturated at 4-6 nM.  
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The Kd values for progesterone and ZK98299 were 2.46 nM and 2.2 nM, 
respectively.  RU38486 is also a GR antagonist; however, in vitro it has been shown 
to be a partial antagonist (Zhang et al., 1995).  ZK98299 differs from RU486 by 
conformation and the substituents on the D-ring of the steroid molecule.  ZK98299 is 
considered a complete antagonist, while RU38486 is considered a partial agonist.  In 
vivo, RU38486 is a partial agonist.  However, in vitro it is a partial or complete 
antagonist depending on the cell line or promoter being studied.  Demonstrating this 
is the fact that in WCL-2 cells, it is agonistic, while in COS-7 cells, it is antagonistic.   
 The rodent MR displays highest affinity for binding aldosterone and 
corticosterone (Reul, et al., 1990).  GR has highest affinity for synthetic 
glucocorticoid steroids, such as RU28362 and dexamethasone, but a lower affinity for 
the naturally occurring cortisol and cortisone. The dog brain model was chosen to 
study the binding characteristics of both MR and GR and their respective ligands.  
Corticosterone has the highest association rate with MR, followed by cortisol, and 
then aldosterone.  The rank order for displacement of aldosterone binding of MR was: 
corticosterone > aldosterone = cortisol > dexamethasone > ZK91587 > RU27652 > 
spironolactone >>>RU 38486.  The rank order of displacement of RU 28362 for the 
dog GR was: RU 28362 >> corticosterone = cortisol > dexamethasone > aldosterone 
> ZK 91587 > RU 26752 = RU 38486 >>> spironolactone.  Because of these 
conclusions, aldosterone and spironolactone are best as an agonist and antagonist, 
respectively, for MR. Triamcinolone acetonide and ZK98299 are best as an agonist 
and antagonist, respectively, for GR.  
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Dexamethasone, although a purported agonist when compared to 
corticosterone, is not specific enough toward GR and was not used in this study.   The 
dexamethasone paradox, as it has been called recently, comes down to the different in 
vivo vs. in vitro binding properties by MR (Reul et al,  2000).  In vivo, 
dexamethasone seems to be an impotent agonist for kidney and brain MR, while 
extensive in vitro studies have shown dexamethasone to bind with high affinity to 
hippocampal MR.  With these and other examples, it seems that dexamethasone’s 
finicky binding is not ideal for this study.   
 It was recently investigated how ligand affinity impacts receptor mobility 
within the living cell (Schaaf et al, 2003).  Through the use of yellow fluorescent 
protein tagged human GRα (hGRα) and fluorescence recovery after photobleaching 
(FRAP), it was found that hGRα exhibits decreased mobility when bound to its 
ligand, and that this decrease in mobility is dependent on ligand affinity towards its 
cognate receptor.  High-affinity ligands induce a larger decrease in receptor mobility 
than low-affinity ligands.  For instance, triamcinolone acetonide and dexamethasone 
(Kd < 5nM) induce a profound decrease in receptor mobility, while cortisone and 
ZK98299 (Kd > 10nM) have little effect on GR mobility.  These data suggest that 
ligand binding induces a conformational change of the receptor, and that this change 
alters the mobility of the receptor.  More so, the affinity of the ligand to its cognate 
receptor may determine the degree of the conformational change of the receptor 
during binding (Schaaf et al, 2003 
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Receptor Involvement in Relation to the Effects of Glucocorticoids on Somatotroph 
Differentiation 
 
 Our group has also investigated involvement of GR during chicken GH cell 
differentiation induced by CORT (Morpurgo et al., 1997).  CORT, progesterone and 
estradiol have been shown to stimulate chicken somatotroph differentiation in vitro as 
seen in the increase in the number of plaque-forming cells as measured by RHPA.  
However, aldosterone had no effect in this study.  The GR antagonist, RU38486 (10-6 
M and 10-9 M), blocked the effects of e16 serum, CORT and progesterone on 
somatotroph differentiation, although an ER antagonist was unable to block the 
effects of CORT on somatotroph differentiation.  This study demonstrates that CORT 
is most likely working through GR and not ER to induce somatotroph differentiation.   
Similarly, pituitary cells isolated from e12 chick embryos were cultured in the 
presence of vehicle, CORT at 1nM, the GR type II antagonist, ZK98299 at 10 uM, 
and CORT and ZK98299 in combination (Bossis & Porter, 2001).   
Immunocytochemistry revealed that treatment with CORT significantly increased the 
population of somatotrophs, however, the effect was not completely blocked, 
although it was reduced, by the antagonist ZK98299.  When this was repeated with 
antagonists toward both GR and MR (spironolactone), the CORT induction was 
completely blocked.  This shows that both receptors are involved in the CORT 
response.  Continuing this study, e12 pituitary cells were pretreated with 10 µM of 
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ZK98299 or RU486 for 1 h before addition of 2 nM of CORT.  The cells were further 
cultured for 36 h and then somtatotroph differentiation was estimated by ICC.  
Neither of the antagonists alone could block the induction by CORT (Bossis & Porter, 
2004).  CORT is still able to induce somatotroph differentiation when GR is blocked, 
which means that CORT is able to activate MR in the absence of GR.   
 Aldosterone was able to induce somatotroph differentiation, lending evidence 
that MR is activated in this response, as well.  Spironolactone, a MR specific-
antagonist, was unable to block the CORT induction of somatotroph differentiation.  
However, the two antagonists, spironolactone and ZK98299, administered together 
were able to block the CORT- or aldosterone-induced somatotroph differentiation in 
e12 pituitary cells in culture.  These results were obtained visually through GH 
staining in ICC.  Similar results were seen using an in situ GH mRNA quantitation 
method developed by the same authors (Bossis & Porter, 1999).  ZK98299 was able 
to attentuate the CORT response by >50% while spironolactone attenuated the 
response by 65%.  The two agents in combination blocked the CORT response by 
>90% (Bossis & Porter, 2004).  
 This study demonstrates that CORT is activating both MR and GR in order to 
induce somatotroph differentiation in e12 chicken pituitary cells.  Through western 
blotting, it was found that GR is present as early as e8 and persisted through e12 
when the study was terminated (Bossis & Porter, 2004).  The beta subunit of MR was 
detected in low levels on e10 and then significantly increased by e12.  The alpha 
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subunit was first detected on e12. Dual labeling immunofluorescence on e12 pituitary 
cells revealed that greater than 95% of GH positive cells also expressed MR. 
 In the brain, MRs seem to be occupied to some degree at basal levels of 
circulating CORT, while GRs are mostly unoccupied (de Kloet et al., 1993).  Coupled 
with the evidence that when the level of circulating CORT increases, GRs become 
occupied after MR saturation (McEwen et al., 1992), it is likely that GR modulates 
CORT’s effects in the brain, while MR has the role of constitutive activation.  
Likewise, GR was expressed in almost all chick e12 pituitary cells (>95%) using a 
gluteraldehyde-based rapid fixation/permeabilization method, suggesting universal 
expression of GR in pituitary cells (Bossis & Porter, 2004).  Using dual fluorescence 
ICC, MR was expressed in greater than 90% of e12 cultured GH-staining cells after 
the cells were treated with CORT for 24 h, lending further evidence that CORT 





 Somatotroph differentiation in the chicken pituitary gland begins around e14 
but can be induced 2 days prematurely both in vitro and in vivo with the 
administration of CORT.  CORT increases both GH mRNA and protein production, 
but protein synthesis of unknown protein(s) is required before induction of GH 
synthesis.  The effects of CORT on GH secretion becomes maximal at e16 after 
which the increased GH production diminishes.  By e20, it seems that somatotrophs 
are unresponsive to CORT’s effects.  The change in responsiveness to CORT may be 
due to a change in the involvement of the type of glucocorticoid receptor that CORT 
is working through.   
In order to determine how the thyroid hormones and CORT interact to 
influence GH production in the pituitary during the second half of chicken embryonic 
development, we cultured embryonic chicken pituitary cells in the presence of CORT 
and T3 as well as agonists and antagonists specific for the glucocorticoid and 
mineralocorticoid receptors.  An ELISA was used to measure GH secreted into the 
cell culture medium.  Through the use of dual-fluorescence immunocytochemistry for 
GH and MR, we were able to determine receptor expression in somatotrophs during 
this period of development. 
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Chapter 2:Somatotropin Response to Corticosterone 
(CORT) and the Thyroid Hormone, T  3, During Chick 





Current research conducted in our lab centers on the differentiation of 
somatotrophs in chickens and the extrapituitary signals that regulate this 
phenomenon. The chicken is a unique model for studies of anterior pituitary 
development because maternal interactions are not a factor as in mammals and the 
egg also allows for easy manipulation of the embryo for a multitude of experiments.   
The glucocorticoid, corticosterone (CORT), is the extrapituitary signal that 
induces final somatotroph differentiation in embryonic chickens, which typically 
occurs on embryonic day (e) 14 (Porter et al., 1995a; Morpurgo et al., 1997; Dean et 
al., 2001).  Administration of CORT induces somatotroph differentiation and a 
significant increase in GH secretion by cultured e12 pituitary cells after two and six 
days in culture, as determined by immunocytochemistry (ICC) and reverse hemolytic 
plaque assay (RHPA), respectively (Dean et al., 2001).  
Pituitary cells appear to become non-responsive to CORT between e16-e20 
(Porter & Dean, 2001), and endogenous CORT peaks at the time of hatching 
(Kalliecharan & Hall, 1974).  Dispersed pituitary cells obtained from e16, e18 and 
e20 chick embryos were treated with CORT for 6, 12 and 18 h while subjected to 
RHPA.  On e16 and e18, CORT increased the number of GH plaque forming cells 
after 18 h.  On e20, CORT significantly increased the number of GH secreting cells 
after 12 h in the RHPA, but this response was lost after 18 h.  After 24 h in the 
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RHPA, all ages tested were unresponsive to CORT.  Results from RHPA require 
careful interpretation during late embryonic chick development because a significant 
increase in GH secretion may be missed as the number of plaque-forming cells 
detected approaches the absolute number of somatotrophs present.  
The apparent difference in responsiveness of somatotrophs from e12 to e16-
e20 to CORT was demonstrated under different experimental conditions and by 
varying assays, e.g. extended culture followed by ICC or acute treatment in the 
RHPA itself.  Directly quantifying GH secretion by pituitary cells at specific intervals 
during the last half of embryonic development with one type of assay under one 
experimental condition will demonstrate more conclusively differences in 
somatotroph responses to CORT during development. 
Somatotroph differentiation and GH secretion are also regulated by the 
thyroid hormones, thyroxine (T4) and triiodothyronine (T3), where T4 must be 
converted to T3 before it has its effects, and T3 modulates the CORT response in a bi-
phasic manner (Liu et al., 2003).  At low doses (0.01 nM), T3 is slightly stimulatory 
alone and augments the CORT effect on GH cell differentiation by e11 pituitary cells.  
At higher doses (1 and 10 nM), T3 antagonizes the CORT response.  T3 suppresses 
GH secretion by pituitary cells obtained from e16 embryos after 32 h in culture and 
this effect is lost by e18, as demonstrated by RHPA (Dean & Porter, 2001).  CORT in 
combination with T3 suppresses GH secretion on e16-e20 after 24 h in culture as 
determined by RHPA.  Clearly, GH secretion induced by CORT is confounded when 
T3 is present as well. 
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Recent evidence shows that CORT induced somatotroph differentiation 
involves both the type I (mineralocorticoid, MR) glucocorticoid receptor and the type 
II (glucocorticoid, GR) glucocorticoid receptor (Bossis & Porter, 2004). CORT 
induced GH cell differentiation in cultured e12 pituitary cells was only blocked when 
treated with both the MR specific antagonist, spironolactone, and the GR specific 
antagonist, ZK98299, as determined by ICC.  GR is expressed in all pituitary cells at 
e12, and MR is co-localized with GH greater than 90% of the time in e12 
somatotrophs, as shown by ICC and dual label immunofluorescence, respectively.  
Investigating CORT induction of somatotrophs using specific glucocorticoid receptor 
agonists and antagonists may elucidate the reason for the apparent change in 
responsiveness to CORT during chick embryonic development.  
In this study, a sandwich enzyme-linked immunosorbent assay (ELISA) for 
chicken GH was used to quantify GH secretion in response to CORT, T3, and GR and 
MR specific antagonists during the last half of chick embryonic development, in 
order to determine, using a unified approach, whether GH responsiveness to CORT is 
lost during chick embryonic development and to assess the involvement of GR and 
MR in this response.      
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Materials and Methods 
 
Animal Use and Cell Culture 
Cell culture reagents were purchased from Gibco Invitrogen (Grand Island, 
NY).  Hormones and other chemicals were obtained from Sigma Chemical Co. (St. 
Louis, MO) unless otherwise noted.  All procedures were approved by the 
Instituitional Animal Care and Use Committee (#R-00-51).  Animals used in this 
study were Avian x Avian strain or Ross x Cobb strain chicken embryos purchased 
from Allen’s Hatchery (Seaford, DE).  Eggs were incubated in a humidified incubator 
(G.Q.F. Manufacturing, Savannah, GA) at 37.5 oC and 60% humidity.  Eggs were set 
in the incubator such that embryos of different embryonic ages were available for 
dissection on the same day.  Pituitaries were removed from embryonic chickens on 
specific days of development using a dissecting microscope and then pooled and 
dispersed with trypsin as previously described (Porter et al, 1995a).  2x105 cells 
suspended in DMEM (Dulbecco’s modified Eagle’s medium, serum free) were 
allowed to attach for one hour in 24-well culture plates and then 0.5 mL of serum-free 
culture medium (SFM; a 1:1 mixture of phenol red-free Medium 199 and Ham’s F12, 
supplemented with 0.1% BSA, 5 ug/mL bovine insulin, 5 ug/mL human transferrin, 
and penicillin/streptomycin) was added.  The plates were incubated for 24 or 72 h in 






M) was added to the culture well for the final six hours of incubation 
to stimulate the release of GH from the cells. After that time, medium was collected 
from each well, centrifuged for 10 minutes at 300 G to remove any loose cells, and 
then the supernatants were frozen at –20 oC for later ELISA analysis. 
Sandwich ELISA for chicken GH 
The sandwich ELISA assay for chicken GH was conducted using the 
monoclonal antibody (mAb), mAb 6F5 (Houston et al, 1991) and the polyclonal 
chicken GH antiserum developed by Porter, 1995a.  Briefly, 96-well Nunc-brand 
Immunosorp© plates were pre-coated with the monoclonal antibody (1 µg/mL in 50 
mM Na2CO3, pH 9.6) overnight at 4 oC as previously described (Houston et al, 1991).  
All incubations were conducted in a 37 oC incubator with several PBS (phosphate 
buffered saline; 100 mM phosphate, 78 mM NaCl, 72 mM KCl, pH=7.4) washes 
between each subsequent incubation.  Samples and standards diluted in 0.1 M 
PBS/0.1% bovine serum albumin (BSA) were added and incubated for 2 hours in a 37 
oC incubator.  Liquid was aspirated and the plates were rinsed 5 times.  The plates 
were blocked (1 M PBS/0.1% BSA/1% normal goat serum (NGS)) for 30 min.  
Liquid was aspirated, and the plates were rinsed 3 times. A polyclonal rabbit anti-
chicken GH antiserum (1:1000) was added for 90 min.  Liquid was aspirated and the 
plates were rinsed 5 times. Goat anti-rabbit IgG biotinylated antibody (1:200) was 
added for 30 min.  Liquid was aspirated, and the plates were rinsed 3 times. The 
plates were incubated with a commercially available goat anti-rabbit avidin-biotin 
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horseradish peroxidase (1:500) for 30 min.  Liquid was aspirated and the plates were 
rinsed 5 times. After that time, tetra-methyl-benzidine (TMB) was diluted per the 
manufacturer’s instructions and was added as the assay substrate.  The plates were 
developed until all wells exhibited some colored product; the development time 
typically lasted for 2 to 5 minutes at room temperature.  The reaction in all wells was 
stopped with the addition of 1 M H2SO4.  The plates were read immediately using a 
Wallac© (Perkin-Elmer) plate reader with the absorbance set at 450 nm.  The 
secondary antibody, enzyme complex (avidin-biotin horseradish peroxidase) and the 
developing reagents (TMB) were obtained from commercial kits (Vector 
Laboratories; Burlingame, CA).  The average GH concentration for each treatment 
was determined from triplicate ELISA wells performed on triplicate cell culture 
wells.   
Statistical Analysis 
 
Each experiment was replicated 4 to 6 times.  Statistically significant 
differences among treatments were determined using a mixed model ANOVA and a 
test of Least Squares Differences (LSD) in the SAS statistical program (SAS Inc; 
Cary, NC).  Values were considered significant at p<0.05.  Data was transformed into 
the log scale to correct for normality and then back-transformed into the geometric 
mean.  Values reported are the geometric mean and one standard error above and 
below the mean.  
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Results 
Validation of Sandwich ELISA for chicken GH  
 
The first specific aim of this project was to establish an ELISA for chicken 
growth hormone, which was adapted from Houston, 1991.  This assay uses a 
monoclonal antibody against chicken GH (generously provided by B. Houston).  The 
polyclonal GH antiserum raised in rabbit was developed and validated in our lab 
(Porter et al., 1995a).  Because very few commercial enzyme kits are available for 
chicken proteins, a biotinylated goat anti-rabbit IgG was used to link the rabbit anti-
chicken GH antiserum to the color-producing enzyme, a strept-avidin conjugated 
horseradish peroxidase.  The biotin-avidin secondary detection system was used to 
amplify the GH signal.  The substrate specific for the peroxidase is hydrogen 
peroxide, while the assay substrate was tetramethylbenzidine, and sulfuric acid was 
used to stop the reaction.     
 To validate an ELISA, four concepts were considered: specificity, sensitivity, 
recovery, and parallelism.  The specificity of the assay is conferred by the 
monoclonal antibody, which binds only chicken GH and not bovine GH, chicken and 
ovine prolactin, luteinizing hormone and porcine follicle-stimulating hormone 
(Houston, 1991).  Specificity is also conferred by the polyclonal antibody that does 
not bind chicken prolactin (Porter, et al., 1995a).  The sensitivity of the assay relates 
to the lowest concentration in the standard curve different from the zero GH standard.  
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In this case, the assay cannot differentiate between 1 ng/mL and 2 ng/mL, but can 
differentiate between 2 ng/mL and 8 ng/mL.  Therefore the sensitivity of the assay is 
roughly 5 ng/mL.  Recovery is the amount of protein detected by the assay in contrast 
to the known amount.  Standard curves prepared in PBS and culture medium were 
used for this.  Cell culture medium was plated in the ELISA wells at three different 
amounts: 10 µL, 30 µL, and 100 µL.  This also changed the amount of buffer in each 
well.  The amount of buffer, ranging from zero percent to 100%, changed the slope 
and results of the standard curve (Figure 1).  Even altering the concentration of 
phosphate in the PBS had little effect on the results.  With the addition of BSA, 
however, the results from standard curves prepared in PBS or culture medium were 
nearly identical, demonstrating both recovery and noninterference by BSA.  Through 
the use of the recombinant chicken GH standard and the secreted cellular GH, the 
ELISA correctly estimated the concentration of GH present, indicative of parallelism.  
The coefficient of variation is a unitless measure of the variability of the data.  
It is determined as the variance divided by the mean of the data set.  If the CV is 
small, then the data has low variance.  The CV estimated for an ELISA is based on a 
known sample that is plated in every plate. In this case, a single well containing the 
32 ng/mL standard was used in each plate. A replicate is defined as one ELISA assay 
using multiple plates was conducted on a single day.  Replicates that used one, two or 
more than four plates were not used to calculate the CV.  Preliminary trials and the 
first experiment did not require log transformation and thus the standard curve is 
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linear; all following experiments were log transformed and therefore two CV’s were 
calculated, one for the linear data and one for the log transformed data.  The inter-
assay CV for the linear data is defined as the variation of the 32 ng/mL standard 
between all replicates (n=9) and was found to be 39.9%.  The inter-assay CV for the 
log transformed data (n=9) and was found to be 30.4%.  The intra-assay CV is 
defined as the variation of the 32 ng/mL standard between multiple (3-4) 96-well 
plates within an assay on a certain date.  The intra-assay CV for the linear data (n=9) 
was found to be 34.0%, while the intra-assay CV for the log transformed data (n=13) 
was found to be 29.3%.  By log transforming the ELISA data, variability was reduced 
and repeatability was increased.  However, the assay remained variable, and greater 
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Figure 1:  Standard Curve Validation.  A) The results of the  
standard curves are dependent on the type of medium in which
they are prepared.  B)  Addition of BSA corrects this.  48
Somatotropin Response to CORT: Preliminary Testing 
 
 During preliminary testing to demonstrate a difference in the CORT response 
between the ages of e12 and e20, a cell culture system and its parameters were 
established.  Previous research demonstrated that protein synthesis was required for 
GH induction in response to CORT (Bossis & Porter, 2003) and maximum secretion 
was reached at 18 h (Dean et al., 1997).  Because of this, e12 somatotrophs would 
have to be cultured for at least 18 h.  The 24 h time-point was chosen for two reasons, 
first, it was enough time for cells to produce and secrete GH, and second, GHRH 
could be added at a reasonable time to induce the cells to release their stored GH.  
Further, the effects of GHRH on somatotrophs are maximal after 8 h and significant 
effects of GHRH are seen after 6 h (Dean et al., 1997).  It has also been demonstrated 
that somatotrophs continue to secrete GH when treated with CORT and GHRH after 
2 and 6 days in culture (Dean & Porter, 1999).  Thus, somatotrophs could be kept in 
culture for up to 6 days, and a GH response to CORT could still be observed.   
From preliminary testing using the sandwich ELISA, e12 cells treated with 
0.5 nM of CORT were not secreting enough GH into the media at the cell density that 
they were plated at for the ELISA to detect differences in basal vs. CORT levels 
using 100 uL of culture medium as the sample.  However, after 72 h in culture with 
the addition of the same concentration of CORT and GHRH added during the final 
six h in culture, the ELISA could detect GH in the cell medium.  Cultured e20 cells 
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produced excessive amounts of GH after both 24 h and 72 h in culture, such that the 
medium had to be diluted (1:50) before assaying it with the ELISA.   
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Experiment I:  Somatotropin GH secretion in response to GHRH, CORT, and 
triiodothyronine, T3, during the last half of chick embryonic development   
 
The objective of the first experiment was to characterize the response of 
somatotrophs to CORT and the thyroid hormones across developmental ages during 
the last half of development using one culture system and one assay system.  
Research conducted in this lab centering on the somatotroph response to CORT 
during development has used multiple different cell culture and assay systems to 
address the effects of CORT on GH secretion at different embryonic ages.  Primary 
pituitary cell cultures have been manipulated with varying times in culture and with 
varying treatments to elucidate the cellular and molecular mechanisms that control 
somatotroph differentiation.  But more importantly, RHPA, ICC, RIA and mRNA 
quantitation have been used extensively and although each individual assay is sound, 
all of them produce slightly different answers to the question.  RHPA relates area of 
plaque produced to quantity of GH secreted.  ICC shows the number of cells 
containing GH and not the amount of GH produced and secreted.  Quantifying 
mRNA directly addresses the levels of the GH transcript but does not address mRNA 
stability, degradation, and the amount of protein being translated.  RIA is the only 
assay, other than ELISA, that directly quantifies the amount of protein secreted.  
However, RIA requires the use of radioactive materials and experience.  ELISA, 
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similar to RIA, quantifies the amount of protein without the use of radioactivity and 
can be completed in one day.  For these reasons, the somatotroph response to CORT 
during the second half of embryonic development was characterized using one culture 
system and a single ELISA. 
Avian x Avian strain fertilized eggs were placed in a 37.5 oC humidified 
incubator such that on the day of the experiment, there were embryos of e12, e14, 
e16, e18 and e20 ages.  The dissected pituitaries from one age were dispersed and 
pooled as previously described (Porter et al., 1995a), plated in triplicate culture wells, 
and treated with CORT (0.5 nM) and T3 (0.5 nM) alone and in combination.  
Dissection of all embryos took one hour and the entire dissection and dispersion was 
completed in 3.5 h.  Six hours before termination of the experiment, the appropriate 
wells were treated with GHRH [10 nM] to stimulate the release of GH into the cell 
culture medium.  The duration of treatment and concentration of GHRH was chosen 
because maximum GH secretion was observed between 4 and 8 h after treatment with 
GHRH (Porter et al., 1995).  After 72 h total culture time, the cell culture medium 
from each well was collected, centrifuged and stored for later ELISA analysis.  Prior 
to freezing, the e14 samples were diluted 1:3 in PBS, e16 samples were diluted 1:10 
in PBS, e18 samples were diluted 1:25 in PBS and e20 samples were diluted 1:50 in 
PBS.  
From this, it was observed that overall GH secretion increased with age 
(Figure 2). The mean basal level of GH secreted by cultured cells obtained from e12 
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pituitary cells was 64.6 ± 6.8 ng/mL (Figure 2).  Addition of GHRH increased the 
mean GH concentration to 140.7 ± 20.0 ng/mL.  However, this apparent effect of 
GHRH alone was not statistically significant.  By e14, the mean GH secreted under 
basal conditions was 335 ± 67 ng/mL, however, the addition of GHRH did not 
increase the secretion any further with a mean of 260 ± 37 ng/mL. On e16, the mean 
GH concentration increased dramatically to 2220 ± 342 ng/mL, but the addition of 
GHRH again did not increase GH concentration (1490 ± 218 ng/mL) over basal 
levels.  At e18, the mean GH secretion was 2926 ± 482 ng/mL under basal conditions.  
Again, GHRH did not increase GH secretion (1881 ± 233 ng/mL).  On e20, the mean 
GH concentration increased further to 7041 ± 1146 ng/mL under basal conditions, 
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Figure 2: Basal GH secretion by cultured pituitary cells
during the last half of chick embryonic development.
Cells were cultured for 72 h and the cell culture medium
was collected for ELISA analysis. Values are the mean ±
SE of 6 replicate experiments. 
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  (5922 ± 945 ng/mL).  It is possible that GH secretion is maximal during the third 
quarter of embryonic development (e14-e20), which is why GHRH did not have an 
effect.  The lack of a response to GHRH [1 nM] alone was observed previously on 
e16 through e20 after 18 h in culture as determined by RHPA (Dean et al., 1997).  
CORT increased GH secretion on e12 and significantly increased it on e14, 
e16 and e18 in the presence of GHRH (Figure 3).  CORT had no effect on GH 
secretion on e20.  CORT treatment increased GH secretion about 1.4-fold over basal 
conditions both with and without GHRH on e12.  On e14, CORT had no effect on GH 
secretion without the presence of GHRH, but produced a significant increase with the 
addition of GHRH as seen in the 2.1-fold increase in GH secretion over that with 
GHRH alone.  Again, on e16, CORT treatment did not significantly increase GH 
secretion without the presence of GHRH.  CORT treatment significantly increased 
GH secretion 1.6-fold with GHRH.  On e18, CORT increased GH secretion, although 
not significantly, under basal conditions and significantly increased GH secretion 
with the addition of GHRH 2.5-fold.  At the end of development, on e20, CORT had 
no effect on GH secretion with or without GHRH. The transitional age from CORT 
responsive to CORT non-responsive was found to be e16.4 using a regression line 
fitting of the entire data set.  Specifically, a regression line was fitted to the basal 
level of GH secretion across the five ages.  A second regression line was fitted to the 
CORT-induced level of GH secretion across the five ages and the point at which the 



























































































































Figure 3: GH secretion by pituitary cells during the last half of embryonic
development.  Cells were treated with CORT and/or T3 [0.5 nM each] for 72 h and
then with (+) or without (-) GHRH [10 nM] during the final six h in culture.  Values
are the mean ± SE of 6 replicate experiments.  Values with different letters denote
significant differences at p < 0.05 within ages. 
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T3 at 0.5 nM had no effect on e12, e14, e16 and e20 (Figure 3).  T3 at the same 
concentration increased GH secretion on e18 from 1881 ± 233 ng/mL to 3852 ± 547 
ng/mL.  When T3 was given in combination with CORT, it was observed that T3 
attenuated the CORT response on e14-e18.  There was no effect of T3 on the CORT 
response seen in e12 and e20 cells.  All cells treated with T3 were also treated with 
GHRH to release stored GH.   
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Experiment II:  Determination of Glucocorticoid Receptor Involvement in the 
Response of Cultured Pituitary Cells to CORT and Modulation by T3 
 
 The specific aim of experiment II was to determine which receptor (GR or 
MR) was used by CORT to induce GH secretion.  Because the somatotroph response 
to CORT changes 1-4 days before hatching, some aspect of CORT induction must 
have changed.  The receptor that CORT is activating is one obvious choice.  CORT 
primarily binds with the type I glucocorticoid receptor, also known as the 
mineralocorticoid receptor (MR), but CORT is also able to bind with the type II 
glucocorticoid receptor (GR).  It is possible that CORT preferentially binds to and 
activates MR from e12 through e16 and then after this time point, MR is either 
sequestered or not expressed and CORT activates GR instead.   
 In order to address this question, this experiment used antagonists and 
agonists of both MR and GR at or slightly above their respective effective 
concentration as demonstrated in relevant literature.  By using these agents at the 
concentration of their Kd, it can be assumed that the agonists and antagonists are only 
activating the receptor that they have the most specificity toward.  For this 
experiment, we chose aldosterone (ALDO) and spironolactone as a MR-specific 
agonist and antagonist, respectively.  The GR-specific agonist and antagonist utilized 
were triamcinolone acetonide (TA) and ZK98299, respectively.  Dexamethasone was 
not chosen as a GR-specific agonist because it has been demonstrated that this agent 
also has a high affinity for MR. Almost all synthetic and natural glucocorticoids and 
 58
mineralocorticoids are able to activate both GR and MR when administered at 
appropriate doses.  For this reason, when choosing agonists and antagonists to use, we 
specifically chose agents that had at least a 10-fold lower affinity for the opposing 
receptor.  And finally, this experiment was designed to determine what effect T3 has 
on this system.   
 Primary pituitary cells obtained from e14 and e20 embryos were used. The 
cells were incubated for 72 h as before.  Both CORT and T3 were used at 1 nM, while 
ALDO was used at 0.5 nM.  The MR specific antagonist, spironolactone, was used 
10-fold higher than ALDO at 5 nM.  The GR antagonist, ZK98299 was used at 5 nM, 
which is the same as spironolactone and also ten-fold higher than ALDO and five-
fold higher than the CORT concentrations used.  CORT and ALDO significantly 
increased GH concentration in the cell culture medium over basal conditions on e14 
and had no effect on e20.  Administration of TA and T3 alone produced no significant 
effect on both e14 and e20.  Addition of the antagonists had no effect on the CORT 
response on both ages.  (Data not shown).  As no effects of the antagonists were 
found, the results of this study were inconclusive and the concentration of the 
agonists and antagonists warranted a more thorough investigation.  
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Experiment III:  Determining the effective concentrations of GR and MR 
specific agonists and antagonists 
  
Because the initial experiment with agonists and antagonists of MR and GR 
did not produce easily interpretable results, the next step was to determine the 
effective concentrations of both the agonists and antagonists in this pituitary cell 
culture system using the sandwich ELISA.  From these results, the concentrations of 
the agents used would not solely be based on relevant literature and physiological 
concentrations, but from actual GH responses. 
 This experiment used the same 72 h incubation time with GHRH being added 
during the final six hours of culture.  The five treatments, CORT, ALDO, TA, 
spironolactonte, and ZK98299 were each administered at three different 
concentrations in three-fold increments, beginning with the concentrations used in the 
previous experiment and increasing the concentration from there.  CORT was 
administered at three doses: 1 nM, 3 nM, and 9 nM.  ALDO was used at 0.5 nM, 1.5 
nM, and 4.5 nM.  TA was initially administered at 0.5 nM, 1.5 nM, and 4.5 nM and 
then in subsequent replicates administered at 0.1667 nM and 13.5 nM.  
Spironolactone was used at 5 nM, 15 nM, and 45 nM initially and then three-fold 
higher again at 0.135 µM.  ZK98299 was similar to spironolactone and administered 
at 5 nM, 15 nM, and 45 nM initially and then higher at 0.135 µM in later trials.  T3 
was dropped from this experimental design because the concentration of T3 was not 
under question and the experimental design became too difficult.   
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The main question that needed to be answered was at what concentration 
would ALDO elicit an increase in GH levels but still be low enough that its specific 
antagonist, spironolactone, would block this response when administered together.  
The same principle was applied to TA and ZK98299.  Furthermore, concentrations of 
the antagonists should be low enough so as not to be stimulatory when administered 
alone or with CORT.  The concentrations of the antagonists were also titered against 
CORT.  Only cells from e14 embryos were used to initially determine effective 
concentrations.   
 The results show that  CORT (1 nM) induced a four-fold increase of GH over 
basal levels (Figure 4A).  There was no effect of CORT on GH secretion at 3 nM and 
9 nM.  The reason for this is not clear, but it may reflect involvement of two receptors 
that elicit different responses.  ALDO did not significantly increase GH secretion at 
any concentration used in this experiment.  Again, TA had no effect on CORT at any 
concentration used.  All of the TA binding and affinity studies referenced used either 
human or rodent cells or isolated receptors and ligands in test tubes.  There was no 
indication from the literature that TA would not elicit an increase in GH secretion in 
embryonic chick pituitary cells.  Spironolactone, the MR antagonist, did not induce 
GH secretion at any concentration used (0.5, 1.5 and 13.5 nM) (Figure 4A).   
The next objective was to determine the effective concentrations of 
spironolactone and ALDO when administered together (Figure 4B).  The specific aim 
was to find a concentration of ALDO that would significantly increase GH secretion 
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Figure 4: GH secretion by e14 anterior pituitary cells in response to (A) varying
concentrations (nM) of CORT, ALDO, TA, and SPIRO.  B) Assessment of
effective concentrations (nM) of ALDO and SPIRO.  Cells were treated with
these agents for 72 h and then treated with GHRH during the final 6 h.  Values
are the back transformed means of log transformed data and plus one standard
error of three replicate experiments.  (*) denotes significant differences from
basal at p < 0.05. (†) denotes significant differences from CORT (1 nM) at p <
0.05. (‡) denotes significant differences from each other at p < 0.05. 62
spironolactone that would block the ALDO-induced GH increase and not have any 
effect on GH secretion when administered alone.  Cultured cells treated with ALDO 
at each of the four concentrations did not increase their GH secretion significantly 
over basal levels.  Because ALDO did not elicit a GH response, it could not be 
determined if spironolactone at a specific concentration would block the ALDO-
induced response.  It has been established that an antagonist can act as an agonist if 
administered at high enough concentrations.  The only significant differences in GH 
secretion were found when ALDO was administered at 13.5 nM in combination with 
spironolactone at 5 nM versus spironolactone at 15 nM (p<0.05).  The results of this 
study were inconclusive, although the most logical concentration of ALDO was 
determined to be 0.5 nM, because it most closely reflected the Kd from the literature 
and elicited a GH response over basal levels, even though the mean response at this 
concentration was not significant.   
The effective concentration of both of the antagonists had yet to be 
determined.  From a previous study conducted in this lab, ZK98299 was used at 10 
µM to block CORT induction of GH secretion (Bossis & Porter, 2004).  This time, 
ZK98299 would be tested at 1 µM, 0.1 µM, and 10 nM to see if any of these 
concentrations were high enough to be stimulatory or could affect CORT induction of 
GH secretion. The same 72 h total culture time was used, agonists and antagonists 
were added to the cell culture wells at the same time, and three complete replicates 
were performed.   
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Spironolactone alone at 5 and 15 nM, but not at 10 or 50 nM, was stimulatory 
to somatotrophs in culture, producing an increase in GH secretion significantly 
different from basal levels (Figure 5).  ZK98299 alone at all three of the 
concentrations tested did not stimulate GH secretion.  When the two antagonists were 
administered together at varying concentrations, some combinations did elicit a 
response of increased GH secretion.  Spironolactone at 15 nM in combination with 
ZK98299 at 10 nM, 100 nM, and 1 µM elicited an increase in GH secretion that was 
significantly different from basal levels.  However, spironolactone at the highest 
concentration of 50 nM in combination with ZK98299 at 10 nM failed to produce the 
same result.  Clearly, the antagonists can act as agonists when given for 72 h at 
inappropriate concentrations.  From these results, spironolactone should not be used 
above 15 nM.   
In this set of experiments, ALDO at 0.5 nM did induce an increase in GH 
secretion (Figure 5).  The addition of 5 nM of spironolactone was not able to block 
this response.  However, the addition of 10 nM of spironolactone caused an even 
greater increase in GH secretion, although not significantly different from ALDO 
alone.  ALDO with spironolactone at 15 and 50 nM produced similar results to 
ALDO with 5 nM of spironolactone.  ZK98299 was unable to block the increase in 
GH secretion by ALDO, although ZK98299 at 100 nM attenuated the ALDO 
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Figure 5: Medium GH concentration of e14 cultured pituitary cells after 
72 h in culture with the antagonists spironolactone (SPIRO) and ZK98299 (ZK98)
and aldosterone (ALDO). GHRH [10 nM] was added during the final six h in
culture.  All concentrations are nanomolar, unless otherwise specified.  Values are
the back transformed means of log transformed data and plus one standard error of
three replicates.  (*) denotes significant differences from basal at p<0.05. (‡)
denotes significant differences from ALDO at p<0.05.  65
  The same experiment was repeated with CORT at 1 nM (Figure 6).  
Spironolactone alone at 1, 5, and 15 nM, but not at 1.5 nM, significantly increased 
GH secretion.  ZK98299 alone at 10 nM, 100 nM, and 1 µM did not elicit a response.  
CORT produced a significant increase in GH secretion over basal levels.  When the 
antagonists were administered with CORT, neither of them blocked the CORT 
induced increase in GH secretion.  When the antagonists were administered together 
with CORT, they again did not block the CORT induced increase in GH secretion.  
Only with spironolactone at 1 nM, ZK98299 at 100 nM and CORT at 1 nM was there 
a decrease in GH secretion.  This apparent decrease was not significantly different 
from CORT alone nor basal levels of GH secretion; it was intermediate. 
 The concentrations of each of the agents used in this experiment were 
examined closely and none of the results were conclusive.  It is possible that CORT  
and ALDO are binding to the receptor first and the antagonists, although at the 
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Figure 6: Medium GH concentration of e14 cultured pituitary cells after 
72 h in culture in order to find effective concentrations of the antagonists SPIRO  
and ZK98 at suppressing the response to CORT.  GHRH [10 nM] was added 
during the final six h in culture.  All concentrations are nanomolar, 
unless otherwise specified.  Values are the back transformed means of log 
transformed  
data and plus one standard error of four replicates.  (*) denotes significant 
differences 
from basal at p<0.05. (†) denotes significant differences from CORT alone at 
p<0.05.  
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Experiment IV:  Pretreatment with Antagonists to Determine Receptor 
Involvement during the CORT response 
 
 Clearly the concentration of the antagonists, although important, was not the 
only factor affecting the outcome of these experiments.  If the cells were pretreated 
with the antagonists for 3 h, giving them time to bind to the receptors without directly 
competing with the agonists, would the outcome be any different? Because of the 
nature of antagonists, meaning that they bind in a different manner than the receptor’s 
cognate ligand, it is possible to assert that even at the perfect concentration of both 
the agonist and the antagonist, the agonist will almost always displace the antagonist 
long enough to produce a biological response.   
The objective of this experiment was to use treatment doses established by the 
previous two experiments, but pretreat with the antagonists to allow time for binding 
to receptors without directly competing with the receptor’s cognate ligand.  The 
overall culture time for this experiment was varied as well.  A 72 h overall culture 
time may be too long of a time for the antagonists to continuously out-compete the 
agonists for the receptors.  Previously, the 72 h culture was used over the 24 h culture 
time to allow the e12 cells from Avian x Avian strain embryos enough time to secrete 
enough GH into the cell culture medium for detection in the ELISA, even though 
both time points were sufficient for GH secretion.  This experiment used Ross x Cobb 
pituitary cells, which produced more GH.  Because of this, the overall culture time 
was varied between 72 h and 24 h.  The following results (Figure 7) are from one trial 
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at 72 h and one trial at 24 h overall culture time.  GHRH was again added at 6 h prior 
to the termination of each of these experiments.    
 Avian x Avian and Ross x Cobb are both broiler strains.  Preliminary results 
from our lab have shown that Ross embryos have a higher abundance of 
somatotrophs than Avian strain embryos at the same age.  Even so, they are still 
responsive to CORT.   
 Three h pretreatment with antagonists allowed time for them to bind to the 
receptors.  A shorter overall incubation time proved effective as well.  For the 24 h 
total culture time, the experiment was terminated 24 h after the addition of the 
antagonists, such that the cells were treated with the agonists for 21 total h.  After 72 
h, CORT increased GH secretion, and inclusion of antagonists did not suppress this 
increase.  In the subsequent experiment, after 24 h, CORT increased GH secretion 
and inclusion of spironolactone alone did not suppress the CORT response.  ZK98299 
alone and in combination with spironolactone appeared to attenuate the CORT 
response.  This suggests that CORT activates either GR or MR to induce GH 
secretion.  Of course, these results should be taken lightly because each experiment 
was only replicated once.  Even so, for subsequent experiments, the 24 h time period 







































































































Figure 7: Effects of 3 h pretreatment with antagonists and overall culture time on GH
secretion by pituitary cells obtained from e12 Ross x Ross strain embryonic chicks.  A)
The antagonists have no effect after 72 h in culture. B) After 24 h in culture, SPIRO still
has no effect, but ZK98 and SPIRO in combination with CORT attenuates the CORT
response.  Values are the geometric mean of triplicate culture wells of one experiment.    
Experiment V:  Pretreatment with Antagonists to Determine Receptor 
Involvement in CORT Responsive vs. CORT Non-responsive Somatotrophs   
 
After the previous experiments, it was found that the most effective approach 
was to culture the cells for 24 h total and pretreat the cells with the antagonists for 
three hours before the addition of the agonists.  The objective of this experiment was 
to test whether both ZK98299 and spironolactone are required to block the CORT 
response on e12 and to determine if receptor involvement is a factor in the loss of 
responsiveness to CORT of pituitary cells late in embryonic development, i.e. e20 
cells.   
Ross x Cobb eggs were set in the incubator such that both e12 and e20 
embryos were dissected on the same day. Cells were pretreated with spironolactone at 
5 nM (low dose) and 15 nM (high dose) and or ZK98299 at 10 nM.  CORT (1 nM) 
and ALDO at 0.5 nM (low dose) and 1.5 nM (high dose) were added to appropriate 
wells 3 h later.  The cells were cultured for 24 h total.  GHRH was added during the 
final 6 h of total culture time, and four replicates were conducted.   
 Cultured pituitary cells obtained from e12 embryos were responsive to CORT 
treatment as seen in the significant three-fold increase in GH secretion (6 ± 3.5 
ng/mL) over basal levels (2 ± 0.95 ng/mL) (Figure 8A).  ALDO at both the high and 
low doses also produced a significant increase in GH secretion.  ALDO at the high 
dose produced a five-fold increase over basal levels, much higher than observed in 
previous experiments, although this response was more variable.  The two 



























































































































































Figure 8: Determination of receptor involvement in the CORT response in GH secretion
by (A) e12 and (B) e20 cultured pituitary cells.  Cells were cultured for 24 h with a 3 h
pretreatment with the antagonists, SPIRO and ZK98.  Concentrations of treatments were
as follows: CORT at 1nM, ALDO at 0.5 nM (L)  and 1.5 nM (H), SPIRO at 5 nM (L) and
15 nM (H), and ZK98 at 10 nM.  Values are the back transformed means of log
transformed data ± pooled standard error of four replicates.  (*) denotes significant
differences from basal at p<0.05.  (†) denotes significant differences from CORT at
p<0.05. (‡) denotes significant differences from ALDO (H) at p<0.05. (#) denotes
significant differences from BASAL, CORT, and ALDO at p<0.05.   72
 stimulate GH secretion. The same result was seen when the cells were treated with 
the two antagonists simultaneously.   
 Addition of ZK98299 suppressed the ALDO induced increase at both the high 
and the low doses.  Spironolactone at the low dose (5 nM) also significantly 
suppressed the low dose ALDO induced GH increase.  However, SPIRO at the low 
dose had no effect on the high dose ALDO response.  Spironolactone at the high dose 
had no effect on either of the doses of ALDO. ALDO was used as a positive control 
for spironolactone; but spironolactone was unable to block all of the ALDO induced 
increases in GH secretion.  Furthermore, inclusion of the two antagonists with ALDO 
at both doses did not suppress the ALDO induced increase in GH.   
 From these observations, it seems that ALDO is inducing GH secretion by e12 
pituitary cells through the GR receptor and not the MR receptor because ZK98299 
attenuated the ALDO response, but spironolactone was ineffective.  Addition of both 
antagonists with ALDO may cause over recruitment of receptors and GH secretion is 
not suppressed because of a high level of activated receptors.  Alternatively, inclusion 
of the MR agonist and antagonist (3 compounds with the capacity to interact with MR 
and/or GR to some extent) may have resulted in GH stimulation through MR 
activation.   
 ZK98299 alone was unable to block the CORT-induced increase in GH 
secretion, and the resultant GH level was neither different from basal nor CORT 
levels.  Spironolactone alone at both the high and low doses was unable to block the 
CORT-induced increase in GH secretion.  However, when both the antagonists were 
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used together in combination with CORT, there was no increase in GH secretion, 
indicating that CORT could induce GH secretion through either GR or MR.   
 Repeating this experiment with cultured pituitary cells obtained from e20 
chick embryos produced unexpected and interesting results (Figure 8B).  Each of the 
four agents alone (CORT, ALDO, ZK98299 and spironolactone) had no effect on GH 
secretion.  ALDO at both doses in combination with ZK98299 significantly 
suppressed GH secretion (235 ± 62 and 210 ± 67 ng/mL) compared to basal levels 
(524 ± 177 ng/mL).  The low dose of ALDO in combination with the low dose of 
SPIRO also significantly suppressed GH secretion (207 ± 44 ng/mL).  GH secretion 
was also suppressed significantly when ALDO at the high dose was administered in 
combination with spironolactone at the high dose and ZK98299.  The combination of 
CORT and the low dose of spironolactone significantly decreased GH secretion (267 
± 83 ng/mL) compared to basal levels (524 ±177 ng/mL).  When the high dose of 
spironolactone was used, suppression of GH secretion (196 ± 48) was significantly 
different from both CORT and basal levels.  With the addition of ZK98299 to CORT 
and spironolactone similar suppressive results were observed.   
 In summary, CORT significantly increases GH secretion by cultured pituitary 
cells obtained from e12 chick embryos, but has no effect on e20. The CORT induced 
increase in GH secretion on e12 was effectively blocked by inclusion of both 
antagonists, spironolactone and ZK98299.  Neither antagonist alone could block the 
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CORT response.  On e20, inclusion of antagonists with CORT or ALDO suppressed 




 A sandwich ELISA for chicken GH to estimate GH secretion by cultured 
chick embryonic pituitary cells was modified from Houston (1991).  The specificity 
of both the monoclonal and polyclonal antibodies was validated previously (Houston 
et al., 1991; Porter et al., 1995a).  Further validation of the assay included estimates 
of sensitivity and repeatability, and demonstration of parallelism.  Addition of BSA to 
samples and standards produced parallel standard curves, regardless of the medium in 
which the samples were suspended.  The interassay CV estimated for this assay was 
35.2%, while the intraassay CV was 31.7%.  With an assay variability of over 30%, 
only two-fold changes or higher in GH concentration could safely be considered 
significantly different.  Even with this variability, however, the ELISA for chicken 
GH has its advantages.  The assay could be completed inexpensively in one day.  This 
ELISA was able to detect differences in GH secretion by pituitary cells during the last 
half of chick embryonic development.  From this assay, basal GH secretion by 
cultured pituitary cells ranges from 65 ng/mL on e12 to 7000 ng/mL on e20, with a 
dramatic increase on e16.  These changes agree with those in endogenous levels of 
circulating GH during chick embryonic development (Scanes, 1987) and the 
ontogeny of GH-secreting cells (Porter et al., 1995a).   
The present results demonstrate that CORT induces GHRH stimulated GH 
secretion in cultured pituitary cells obtained from e12 to e18 and that this effect is lost 
by e20.  Previous work has demonstrated that CORT can increase the number of GH 
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producing cells among cultured e12 pituitary cells using ICC and RHPA (Morpurgo 
et al., 1997; Dean & Porter, 1999; Bossis & Porter, 2001).  In a follow-up paper, e16-
e20 somtatrophs were no longer responsive to CORT after 24 h in culture in an 
RHPA (Porter & Dean, 2001).  Estimation of secretion by RHPA requires that the 
cells be cultured in small amounts of medium and possibly for an extended amount of 
time.  Although the pituitary cells obtained from embryos later in development were 
repeatedly unresponsive to CORT, it is possible that the unresponsiveness was due to 
an assay artifact.  ICC, RHPA, and ELISA are inherently different in what they 
measure.  ICC estimates GH containing cells, while RHPA demonstrates GH 
secreting cells.  Neither of these assays quantifies the level of GH secretion, which 
can be done with an ELISA.  Moreover, the previous findings were determined under 
varying experimental conditions.  The present study is the first time that the loss of 
responsiveness to CORT by e20 pituitary cells during late chick embryonic 
development has been demonstrated using the same experimental and assay 
conditions used to show stimulatory effects on e12. GH secretion by the pituitary is at 
a maximum as GH peaks just prior to hatching (Scanes, 1974), which may be why 
CORT is unable to elicit a response over already increased GH secretion.  
Alternatively, the change in responsiveness may reflect differences in receptor levels, 
occupancy, or involvement. 
 Our results demonstrate that the somatotroph response to CORT is modulated 
by T3 only on specific embryonic ages in development.  E12 pituitary cells are 
unresponsive to the combination of CORT and T3 after 3 days in culture.  However, 
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on e14 and e16, T3 suppresses the CORT-induced increase in GH secretion.  On e16 
and e18, T3 alone increases GH secretion over basal levels and this effect is lost by 
e20.  There was no combined effect of CORT and T3 on e18 or e20 relative to basal 
and CORT treated.  Other studies have demonstrated that the combined effect of 
CORT and T3 is super stimulatory on e11 after three and six days in culture (Liu et 
al., 2003), but by e16, the combined effect was inhibitory to acute GH secretion 
(Porter & Dean, 2001).  One explanation for the differing results may be that these 
two studies used different culture conditions and different assays to determine the 
effects of glucocorticoids and T3 on GH secretion.  However, it is well known that 
glucocorticoids and thyroid hormones interact to affect GH gene transcription in rats 
(Evans et al., 1982; Shapiro et al., 1978).  Thyroid hormones induce GH synthesis 5- 
to 20-fold, and cortisol increases this response 2- to 6-fold higher in cultured rat GH1 
cells (Shapiro et al., 1978).  In rat pituitary GH3 cells, the effects of T3 on the thyroid 
hormone receptor (TR) and GR were studied in parallel with T3 and dexamethasone 
(DEX) treatment on GH gene transcription (Williams et al., 1991). T3 and DEX 
increased GH gene transcription, both alone and in combination, and this effect was 
still observed while TR and GR mRNA levels were reduced.  This is evidence that 
receptor presence is not the only factor regulating GH gene transcription.  TR is also 
part of the nuclear/steroid receptor superfamily.  Studies have shown that TR can 
form heterodimers with the Vitamin D receptor (Kliewer et al., 1992; Zhang et al., 
1992).  It is possible that heterodimerization of TR and GR/MR is one modulator of 
GH gene transcription.  Whether the responses involve direct interactions of nuclear 
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receptors or not, the present results demonstrate that the nature of the GH response to 
CORT and T3 changes during development. 
 It was hypothesized that the change in responsiveness to CORT from e12 to 
e20 may be due to a change in glucocorticoid receptor involvement.  Cultured e14 
pituitary cells were treated for 72 h with GR and MR specific antagonists, ZK98299 
and spironolactone, respectively.  The antagonists exhibited unexpected paradoxical 
effects on GH secretion after this amount of time in culture.  By definition, 
antagonists should not decrease basal activities, but only suppress a given response.  
Spironolactone at most concentrations tested paradoxically stimulated GH secretion.  
ZK98299 alone was not stimulatory. The two antagonists in combination with an 
agonist were also stimulatory.  After reducing the culture time to 24 h and pretreating 
e12 pituitary cells with the antagonists, the same concentrations of the antagonists (5 
nM and 10 nM) were no longer stimulatory, and when given in combination with an 
agonist suppressed GH secretion relative to the agonist alone.  It appears that the 
concentration of the antagonist was not in excess, rather the amount of time the cells 
were incubated with the antagonists produced the paradoxical effects.  No evidence of 
these unexpected effects of the antagonists could be found in the literature.  Pituitary 
cells and cell lines have been treated with agonists, such as CORT, dexamethasone 
and triamcinolone acetonide, for as long as 6 days in culture without producing 
anomalous effects (Sve, 1984; Dean et al., 1999).  The paradoxical effects of long 
term exposure to these glucocorticoid receptor specific antagonists in chick 
embryonic pituitary cells warrants a more thorough investigation.   
 79
Treatment with a GR specific antagonist, ZK98299, or a MR specific 
antagonist, spironolactone alone, did not abolish the CORT mediated induction of GH 
secretion by e12 pituitary cells after 24 h in culture, but treatment with both 
antagonists completely blocked the effect of CORT on GH.  This suggests that CORT 
can exert its actions through either GR or MR to induce GH secretion.  If GR is 
blocked, then MR is activated to affect GH secretion, and likewise for MR. Induction 
of GH by both MR and GR has also been demonstrated by estimating the number of 
GH containing cells using ICC when treated with these same receptor specific 
antagonists (Bossis & Porter, 2004).  GR is expressed in almost every pituitary cell 
type on e12, and using dual-labeling immunofluorescence, e12 GH containing cells 
co-expressed MR greater than 95% of the time (Bossis & Porter, 2004).  GR and GH 
were colocalized in 98% of cells in the rat anterior pituitary as well (Ozawa et al., 
1999).  It is believed that in the adult brain MRs are occupied with basal levels of 
CORT most of the time and that GRs are mostly unoccupied (de Kloet et al., 1993).  
Further, when the circulating level of CORT increases, GRs are activated after MR 
saturation in neuronal tissue (McEwen et al., 1992).  Thus, GH secretion in response 
to low levels of CORT may be mediated primarily through MR, but when CORT 
levels rise, GRs become activated as well.  This is further supported by the finding 
that GR and MR are known to heterodimerize, and upon heterodimerization, DNA 
specific binding is greatly increased (Trapp et al., 1994).  Because the two receptors 
are expressed in the majority of pituitary somatotrophs on e12, heterodimerization of 
receptors may play an important role in the hypothalamic-pituitary-adrenal axis, 
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while heterodimerization in peripheral tissues, such as the liver where MR expression 
is low, is less critical (Funder, 1993). 
It appears that receptor involvement does not change by e20 in chick 
embryonic pituitary cells, however, enigmatic effects were observed.  On e12, 
treatment with either MR or GR antagonists alone did not block CORT induced GH 
secretion, and inclusion of both antagonists was required to block CORT induction of 
GH secretion.  On e20, inclusion of antagonists alone did not suppress GH secretion; 
rather the addition of CORT and ALDO with antagonists was GH suppressive.  These 
findings of inhibitory effects of MR and GR selective antagonists on e12 and e20 
suggest that both receptors are expressed in somatotrophs throughout chick 
embryonic development.  That said, the suppression of basal GH secretion by MR 
and GR antagonists with an agonist on e20 is enigmatic.  However, at e20, prior to 
hatching, endogenous CORT is high.  One hypothesis is that endogenous CORT may 
have been carried over from the intact embryo through to the primary pituitary 
culture, where GR and/or MR were already affecting GH gene transcription.  High 
levels of endogenous CORT may also explain the unresponsiveness of e20 pituitary 
cells to CORT in culture; they may have already been maximally stimulated by 
endogenous glucocorticoids.  This hypothesis is unlikely because inclusion of both 
antagonists without an agonist present should have suppressed GH secretion and this 
was not observed.  Moreover, during the dispersion process, cells are bathed in 
CORT-free medium, diluting the concentration of any endogenous CORT.  Further, 
the cells are washed three times in fresh medium that would wash away any 
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endogenous CORT.  Activation of the glucocorticoid receptors by appropriate ligands 
causes the translocation of the receptor from the cytoplasm to the nucleus, where 
binding of the receptor ligand complex initiates gene transcription.  The inclusion of 
the antagonists with an agonist, thereby activating both GR and MR, may have 
caused a conformational change in the receptors resulting in the suppression of 
normally expressed gene products, while increasing transcription of gene products yet 
to be determined.   
In summary, glucocorticoids increase GH secretion during the last half of 
chick embryonic development until just prior to hatching, when the cells are no 
longer responsive.  Thyroid hormones modulate this effect.  Both type I (MR) and 
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